These findings indicate that our lactylation risk model can be used to predict the malignant progression and immune evasion of breast cancer. It is expected to become a potential therapeutic target and a diagnostic marker for breast cancer. This model also provides insights into breast cancer therapy and an effective framework for developing gene screening models applicable to other diseases and pathogenic mechanisms.
Lina Tang (Tue,) studied this question.